A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Inclusion Criteria:

* Adults greater than 18 years of age with documented HIV infection
* Highly active antiretroviral therapy (HAART) regimens as defined by the Department of Health and Human Services guidelines; stable regimens for 12 weeks.
* CD4 greater than 200 at time of study enrollment
* Stable monitoring labs (hematology survey with differential, ALT, creatinine)
* Absolute neutrophil count within normal limits

Exclusion Criteria:

* AIDS defining illness within the last 6 months
* Acute bacterial, viral, or fungal infection within the last 1 month, or history of recurring infections
* Women who are pregnant or nursing
* Hypersensitivity to etanercept
* Previous use of etanercept
* Acute malignancy in the last 5 years excluding in situ cervical cancer (CA) and common skin cancers (non melanoma)
* History of active or latent tuberculosis
* History of demyelinating nerve disease
* History of seizure disorder
* Latex allergy
* Subject has any of the following laboratory values within 30 days of baseline:

  * hemoglobin concentration \< 10.0 g/dl for men and \< 9.0 g/dl for women
  * platelet count \< 75,000/mm3
  * AST or ALT \> 5x upper limit of normal (ULN)
  * serum creatinine \> 2.5x ULN
  * serum pancreatic amylase \> 1.5 ULN
* Subject requiring treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferon
* Subjects who chronically use any over-the-counter (OTC) or prescription medication (except vitamins) must not change the regimen or switch their medication within 3 days of drug administration and until discharged from the study.